Onyx submits multiple myeloma drug for FDA approval

Less than two years after buying Proteolix Inc. and its lead drug candidate, carfilzomib, Onyx Pharmaceuticals Inc. is asking federal regulators to approve the experimental multiple myeloma treatment.
South San Francisco-based Onyx (NASDAQ: ONXX) said it submitted a completed new drug application to the Food and Drug Administration, seeking accelerated approval for carfilzomib. Onyx, which had already won fast-track status for carfilzomib, had been submitting the application on a rolling basis since January.
Analysts have said that carfilzomib could hit $1 billion in annual sales.